BRAF and melanoma: In contrast, AXL inhibition in BRAF mutant melanoma may be more effective in PTEN wild-type patients, as phosphorylated AXL is only significantly increased in BRAF inhibitor-resistant cell lines in the context of endogenous PTEN [316].